ASCL1 and LHX8 methylation in HPV-positive self-collected samples 97 4 CIN3+ sensitivity of 88.9% (95% CI 81.6-96.1%) with a corresponding specificity of 57.0% (95% CI 52.3-61.8%). The relative sensitivity of the combination of HPV16/18 genotyping with ASCL1/LHX8 methylation analysis versus cytology triage on a paired clinician-collected cervical sample for CIN3+ was 1.00 (95% CI 0.89-1.13) and the relative specificity 0.83 (95% CI 0.75-0.92). METHYLATION LEVELS IN PAIRED SELF-COLLECTED SAMPLES, CLINICIANCOLLECTED SAMPLES AND TISSUE SPECIMENS Paired ASCL1/LHX8 methylation data on self-collected and clinician-collected samples Controls CIN2 CIN3+ N Methylation positivity 95% CI N Methylation positivity 95% CI N Methylation positivity 95% CI HPV16/18 121 38.8% (30.2-47.5%) 14 42.9% (16.9-68.8%) 55 74.5% (63.0-86.1%) Other alpha-7/9* 191 35.6% (28.8-42.4%) 32 50.0% (32.7-67.3%) 29 72.4% (56.1-88.7%) Non-alpha-7/9** 119 30.3% (22.0-38.5%) 15 46.7% (21.4-71.9%) 12 58.3% (30.4-86.2%) *other-alpha-7/9 types: HPV 31, 33, 35, 39, 45, 52, 58, 59 and 68 ** non-alpha-7/9 types: HPV 51, 56 and 66 Number 100 90 80 70 60 50 40 30 20 10 0 51 56585966 183133353945 52 HPV types 16 68 51 56585966 183133353945 52 HPV types 16 68 51 56585966 183133353945 52 HPV types 16 68 Controls CIN2 CIN3+ methylated unmethylated Figure 4.3 ASCL1/LHX8 marker panel outcome according to HPV genotype stratified for disease category. Multiple HPV infections were counted as separate attributions. Abbrevations: HPV, human papillomavirus; CIN, cervical intraepithelial neoplasia; N, total number of samples; CI, confidence interval
RkJQdWJsaXNoZXIy MjY0ODMw